Neonatology
Original Paper
Gastric Emptying of Preterm Neonates Receiving DomperidoneGounaris A.a · Costalos C.c · Varchalama E.b · Kokori F.b · Grivea I.N.d · Konstantinidi K.a · Syrogiannopoulos G.A.daNICU and bDepartment of Ultrasonography, General Hospital ‘Agios Panteleimon’, Nikea, cNICU, General Hospital ‘Alexandra’, Athens, and dDepartment of Pediatrics, University General Hospital, University of Thessaly, School of Medicine, Larissa, Greece
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: August 07, 2008
Accepted: December 15, 2008
Published online: July 31, 2009
Issue release date: December 2009
Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2
ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)
For additional information: https://www.karger.com/NEO
Abstract
Objectives: Immature gut motility in very low birth weight infants causes feeding intolerance. We evaluated the effect of domperidone, a prokinetic agent, on gastric emptying in very low birth weight infants. Methods: The study was conducted in a crossover design. Gastric emptying was assessed ultrasonographically by measuring the time it took the antral cross sectional area of the stomach to reach half of the value of the 1st measurement on 2 occasions: (1) upon administration of domperidone (0.3 mg/kg/8 h p.o.) for at least 2 days and (2) while patients received an equal quantity of sterile water. 11 infants were randomly assigned to receive domperidone before the 1st measurement and the remaining afterwards. There was a 3–5 day interval between the 2 measurements. At the time when both measurements were performed, every neonate had been receiving the same quantity and quality of milk. 12 infants were formula-fed while 10 were fed their own mother’s supplemented milk. Results: 22 infants with a mean (SD) birth weight of 1,377 g (319) and a mean (SD) gestational age of 30.2 weeks (2.1) were studied. The mean (SD) antral cross sectional area half-value time (in minutes) was 47.6 (23.9) in the domperidone group and 68.2 (25.5) in the control group (p = 0.008). There was no significant difference between formula-fed neonates and neonates fed their own mother’s milk in either group. Conclusions: Domperidone significantly reduces gastric emptying in preterm neonates, and this may account for its effect in cases of disturbances related to gut motility.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Grand RJ, Watkins JB, Torti FM: Development of the human gastrointestinal tract: a review. Gastroenterology 1976;70:790–810.
- Lau C, Smith EO, Schanler RJ: Coordination of suck-swallow and swallow respiration in preterm infants. Acta Paediatr 2003;92:721–727.
- Berseth CL: Gestational evolution of small intestine motility in preterm and term infants. J Pediatr 1989;115:646–651.
- Riezzo G, Indrio F, Montagna O, et al: Gastric electrical activity and gastric emptying in term and preterm newborns. Neurogastroenterol Motil 2000;12:223–229.
- Vandenplas Y, Hauser B, Salvatore S: Current pharmacological treatment of gastroparesis. Expert Opin Pharmacother 2004;5:2251–2254.
- Bines JE, Quinlan JE, Treves S, et al: Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992;14:400–405.
- Newell SJ, Chapman S, Booth IW: Ultrasonic assessment of gastric emptying in the preterm infant. Arch Dis Child 1993;69:32–36.
- Lucas A, Morley R, Cole TJ: Randomized trial of early diet in preterm babies and later intelligence quotient. BMJ 1998;317:1481–1487.
- Berseth CL: Gastrointestinal motility in the neonate. Clin Perinatol 1996;23:179–190.
- Richter JE, Sabesin SM, Kogut DG, et al: Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996;91:1766–1772.
- Machida HM, Fortes DA, Gall DG, et al: Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988;112:483–487.
- Blumenthal I, Costalos C: The effect of metoclopramide on neonatal gastric emptying. Br J Clin Pharmacol 1977;4:207–208.
- Putman PE, Orenstein SR, Wessel HB, et al: Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992;121:983–985.
- Ramirez B, Richter JE: Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:5–20.
- Levi P, Marno F, Saluzzo C, et al: Betanechol versus antacides in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985;40:349–359.
- Ng SC, Gomez JM, Rajadurai VS, et al: Establishing enteral feeding in preterm infants with feeding intolerance: a randomized controlled study of low dose erythromycin. J Pediatr Gastroenterol Nutr 2003;37:554–558.
-
Costalos C, Gounaris A, Varchalama E, et al: Erythromycin as a prokinetic agent in preterm infants. J Pediatr Gastroenterol Nutr 2002;32:23–25.
- Vandenplas Y, Belli DC, Benatar A, et al: The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 1999;28:518–528.
- Barbey JT, Lazzara R, Zipes DR: Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther 2002;7:65–76
- Barone JA: Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999;33:429–440.
- Champion MC, Hartnett M, Yen M: Domperidone, a new dopamine antagonist. CMAJ 1986;135:457–461.
- Reddymasu SC, Soykan I, McCallum RW: Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036–2045.
- Rocha CM, Barbosa MM: QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005;26:720–723.
- Djeddi D, Kongolo G, Lefaix C, et al: Effect of domperidone on QT interval in neonates. J Pediatr 2008;153:663–666.
- Takahashi T, Kurosawa S, Wiley JW, et al: Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs. Gastroenterology 1991;101:703–710.
- Patterson D, Abell T, Rothstein R, et al: A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230–1234.
- Bateman DN, Gooptu D, Whittingham TA: The effects of domperidone on gastric emptying of liquid in man. Br J Clin Pharmacol 1982;13:675–678.
- Itoh H, Katagiri F, Ikawa K, et al: Effects of domperidone on human plasma levels of motilin, somatostatin, gastrin, adrenocorticotropic hormone and cortisol. Biol Pharm Bull 2005;28:1752–1756.
- Bode S, Dreyer M, Greisen G: Gastric emtying and small intestinal transit time in preterm infants: a scintigraphic method. J Pediatr Gastroenterol Nutr 2004;39:378–382.
- Gomes H, Hornoy P, Liehn JC: Ultrasonography and gastric emptying in children: validation of a sonographic method and determination of physiological and pathological patterns. Pediatr Radiol 2003;33:522–529.
- Gounaris A, Kokori F, Varchalama L, et al: Theophylline and gastric emptying in VLBW neonates – a randomized control trial. Arch Dis Child Fetal Neonatal Ed 2004;89:F297–F299.
- Ewer AK, Durbin GM, Morgan ME, et al: Gastric emptying in preterm infants. Arch Dis Child Fetal Neonatal Ed 1994;71:F24–F27.
- McClure RJ, Newell SJ: Effect of fortifying breast milk on gastric emptying. Arch Dis Child Fetal Neonatal Ed 1996;74:F60–F62.
Article / Publication Details
Received: August 07, 2008
Accepted: December 15, 2008
Published online: July 31, 2009
Issue release date: December 2009
Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 2
ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)
For additional information: https://www.karger.com/NEO
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
